BRAF and metastatic melanoma: We conducted a Phase II trial to assess the clinical activity of continued BRAF inhibition, with the addition of chemotherapy, in patients with BRAF-mutated metastatic melanoma and systemic PD during vemurafenib treatment as single agent.